Abstract: Hepatitis GB Virus (HGBV) nucleic acid and amino acid sequences useful for a variety of diagnostic and therapeutic applications, kits for using the HGBV nucleic acid or amino acid sequences, HGBV immunogenic particles, and antibodies which specifically bind to HGBV. Also provided are methods for producing antibodies, polyclonal or monoclonal, from the HGBV nucleic acid or amino acid sequences.

Abstract: The subject invention relates to the identification of several genes involved in the elongation of polyunsaturated acids (i.e., “elongases”) and to uses thereof. At least two of these genes are also involved in the elongation of monounsaturated fatty acids. In particular, elongase is utilized in the conversion of gamma linolenic acid (GLA) to dihomogamma linolenic acid (DGLA) and in the conversion of AA to adrenic acid (ADA), or eicosapentaenoic acid (EPA) to &ohgr;3-docosapentaenoic acid (DPA). DGLA may be utilized in the production of polyunsaturated fatty acids, such as arachidonic acid (AA), docosahexaenoic acid (DHA), EPA, adrenic acid, &ohgr;6-docosapentaenoic acid or &ohgr;3-docosapentaenoic acid which may be added to pharmaceutical compositions, nutritional compositions, animal feeds, as well as other products such as cosmetics.

Abstract: The present invention relates to an efficient process for the preparation of 5-(substituted)-10-methoxy-2,2,4-trimethyl-2,5-dihydro-1H-chromeno[3,4-f]quinolines.

Abstract: The subject invention relates to the identification of genes involved in the desaturation of polyunsaturated fatty acids at carbon 5 (i.e., “&Dgr;5-desaturase”) and at carbon 6 (i.e., “&Dgr;6-desaturase”) and to uses thereof. In particular, &Dgr;5-desaturase may be utilized, for example, in the conversion of dihomo-&ggr;-linolenic acid (DGLA) to arachidonic acid (AA) and in the conversion of 20:4n-3 to eicosapentaenoic acid (EPA). Delta-6 desaturase may be used, for example, in the conversion of linoleic (LA) to &ggr;-linolenic acid (GLA). AA or polyunsaturated fatty acids produced therefrom may be added to pharmaceutical compositions, nutritional compositions, animal feeds, as well as other products such as cosmetics.

Abstract: A set of contiguous and partially overlapping cDNA sequences and polypeptides encoded thereby, designated as CS 198 and transcribed from GI tract tissue, is described. These sequences are useful for detecting, diagnosing, staging, monitoring, prognosticating, preventing or treating, or determining the predisposition of an individual to diseases and conditions of the GI tract, such as GI tract cancer. Also provided are antibodies which specifically bind to CS 198-encoded polypeptide or protein, and agonists or inhibitors which prevent action of the tissue-specific CS 198 polypeptide, which molecules are useful for the therapeutic treatment of GI tract diseases, tumors or metastases.

Abstract: The subject invention relates to monovalent oligosaccharides and their use, for example, in the treatment and prevention of mammalian disease caused by infection with Shiga toxin (ST) or Shiga-like toxin (SHL). In particular, the trisaccharide globotriose (i.e., galactose &agr;1,4 galactose &bgr;1,4 glucose) may be used to competitively inhibit binding of the toxins to their cellular targets.

Abstract: Hepatitis GB Virus (HGBV) nucleic acid and amino acid sequences useful for a variety of diagnostic and therapeutic applications, kits for using the HGBV nucleic acid or amino acid sequences, HGBV immunogenic particles, and antibodies which specifically bind to HGBV. Also provided are methods for producing antibodies, polyclonal or monoclonal, from the HGBV nucleic acid or amino acid sequences.

Abstract: Hepatitis GB Virus (HGBV) nucleic acid and amino acid sequences useful for a variety of diagnostic and therapeutic applications, kits for using the HGBV nucleic acid or amino acid sequences, HGBV immunogenic particles, and antibodies which specifically bind to HGBV. Also provided are methods for producing antibodies, polyclonal or monoclonal, from the HGBV nucleic acid or amino acid sequences.

Abstract: This invention relates generally to a multimeric polypeptide complex/antigen which may be utilized in detecting or diagnosing diseases of the breast such as breast cancer. Furthermore, the invention relates to methods and kits, for example, which utilize this antigen or an antibody thereto. The complex itself comprises at least one BU101 polypeptide and at least one Mammaglobin polypeptide. In addition, the complex may comprise at least one polypeptide having at least 20% identity with the amino acid sequence of the BU101 polypeptide, the amino acid sequence of the Mammaglobin polypeptide, and fragments thereof.

Abstract: The present invention relates to an efficient process for the preparation of 5-(substituted)-10-methoxy-2,2,4-trimethyl-2,5-dihydro-1H-chromeno[3,4-f]quinolines.

Abstract: This invention is biological in nature and relates to the synthesis, structure and biological activities of novel &agr;-1,2 and &agr;-1,3 fucosyltransferases from Caenorhabditis elegans (“C. elegans”). The present invention also contemplates a transgenic non-human eukaryotic mammal whose germ cells and somatic cells incorporate cDNA sequences encoding one or more of the novel &agr;-1,2 and &agr;-1,3 fucosyltransferases from C. elegans, introduced into the non-human eukaryotic mammal, or an ancestor of the non-human eukaryotic mammal, at an embyonic stage.

Abstract: The subject invention relates to improvements in nucleic acid isolation, and more particularly, relates to modifications to the subtractive hybridization method and to reagents such as oligonucleotides that are useful when performing the method.

Abstract: Hepatitis GB Virus (HGBV) nucleic acid and amino acid sequences useful for a variety of diagnostic and therapeutic applications, kits for using the HGBV nucleic acid or amino acid sequences, HGBV immunogenic particles, and antibodies which specifically bind to HGBV. Also provided are methods for producing antibodies, polyclonal or monoclonal, from the HGBV nucleic acid or amino acid sequences.

Abstract: The subject invention relates to the identification of a gene involved in the desaturation of polyunsaturated fatty acids at carbon 5 (i.e., “human &Dgr;5-desaturase”) and to uses thereof. In particular, human &Dgr;5-desaturase may be utilized, for example, in the conversion of dihomo-&ggr;-linolenic acid (DGLA) to arachidonic acid (AA) and in the conversion of 20:4n-3 to eicosapentaenoic acid (EPA). AA or polyunsaturated fatty acids produced therefrom may be added to pharmaceutical compositions, nutritional compositions, animal feeds, as well as other products such as cosmetics.

Abstract: The subject invention relates to the identification of a gene involved in the desaturation of polyunsaturated fatty acids at carbon 5 (i.e., “human &Dgr;5-desaturase”) and to uses thereof. In particular, human &Dgr;5-desaturase may be utilized, for example, in the conversion of dihomo-&ggr;-linolenic acid (DGLA) to arachidonic acid (AA) and in the conversion of 20:4n-3 to eicosapentaenoic acid (EPA). AA or polyunsaturated fatty acids produced therefrom may be added to pharmaceutical compositions, nutritional compositions, animal feeds, as well as other products such as cosmetics.

Abstract: The subject invention relates to the identification of a gene involved in the elongation of polyunsaturated fatty acids (i.e., “elongase”) and to uses thereof. In particular, elongase is utilized in the conversion of gamma linolenic acid (GLA) to dihomogamma linolenic acid (DGLA) and in the conversion of 20:4n-3 to eicosapentaenoic acid (EPA). DGLA may be utilized in the production of polyunsaturated fatty acids, such as arachidonic acid (AA) which may be added to pharmaceutical compositions, nutritional compositions, animal feeds, as well as other products such as cosmetics.

Abstract: The subject invention relates to a promoter which induces expression of the myostatin gene as well as to methods for identifying compositions useful for the inhibition of the promoter, and also methods and compositions useful for preventing the synthesis, secretion and function of myostatin. In particular, inhibitors that prevent the synthesis, secretion and function of myostatin may be used to prevent the loss of muscle mass in humans and animals.

Abstract: The present invention relates to nucleic oligomer primers or probes useful for detection of TTV in test samples. Also provided are assays which utilize these primers and probes, as well as test kits which contain these oligomer primers and/or probes. In addition, the present invention encompasses the use of TTV nucleotide sequences as nucleic acid vectors and as markers for determining transmission between individuals as well as the route thereof. Additionally, the present invention encompasses a method of detecting TTV infection prior to xenotransplatation of a tissue or organ.

Abstract: This invention relates generally to a multimeric polypeptide complex/antigen which may be utilized in detecting or diagnosing diseases of the breast such as breast cancer. Furthermore, the invention relates to methods and kits, for example, which utilize this antigen or an antibody thereto. The complex itself comprises at least one BU101 polypeptide and at least one Mammaglobin polypeptide. In addition, the complex may comprise at least one polypeptide having at least 20% identity with the amino acid sequence of the BU101 polypeptide, the amino acid sequence of the Mammaglobin polypeptide, and fragments thereof.

Abstract: A set of contiguous and partially overlapping cDNA sequences and polypeptides encoded thereby, designated as CS193 and transcribed from GI tract tissue, are described. These sequences are useful for the detecting, diagnosing, staging, monitoring, prognosticating, preventing or treating, or determining the predisposition of an individual to diseases and conditions of the GI tract, such as GI tract cancer. Also provided are antibodies which specifically bind to CS193-encoded polypeptide or protein, and agonists or inhibitors which prevent action of the tissue-specific CS193 polypeptide, which molecules are useful for the therapeutic treatment of GI tract diseases, tumors or metastases.